Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma

Ronald J C L M Vuylsteke, Paul J. Borgstein, Paul A M Van Leeuwen, Hester A. Gietema, Barbara G. Molenkamp, Markwin G Statius Muller, Paul J. Van Diest, Joost R M Van Der Sijp, Sybren Meijer

Research output: Contribution to journalArticle

Abstract

Even though 60% to 80% of melanoma patients with a positive sentinel lymph node (SLN) have no positive additional lymph nodes (ALNs), all these patients are subjected to an ALN dissection (ALND) with its associated morbidity. The aim of this study was to predict the absence of ALN metastases in patients with a positive SLN by using features of the primary melanoma and SLN tumor load. Of 71 SLN-positive patients, 52 had metastasis limited to the SLN (group 1), and 19 had 1 positive ALN after ALND (group 2). The tumor load of the SLN was assessed by measuring the total surface area by computerized morphometry. Breslow thickness, ulceration and lymphatic invasion of the primary tumor, and total SLN metastatic area were tested as covariates predicting the absence of positive ALNs. The mean SLN metastatic area was 1.18 mm2 (group 1) and 3.39 mm2 (group 2) (P = .003) and was the only significant and independent factor after multivariate analysis (P = .02). None of the patients with both a Breslow thickness 2 had a positive ALN. SLN metastatic area can be used to predict the absence of positive ALNs in melanoma patients. In this study, patients with a Breslow thickness 2 seemed to have no positive ALN and had excellent survival. We hypothesize that this subgroup might not benefit from ALND. Prospective larger trials, using this model and randomizing between ALND and no ALND, should confirm this hypothesis.

Original languageEnglish (US)
Pages (from-to)440-448
Number of pages9
JournalAnnals of Surgical Oncology
Volume12
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Tumor Burden
Melanoma
Lymph Nodes
Survival
Dissection
Neoplasm Metastasis
Sentinel Lymph Node
Lymph Node Excision
Multivariate Analysis
Morbidity

Keywords

  • Additional lymph node
  • Melanoma
  • Metastatic area
  • Sentinel lymph node

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Vuylsteke, R. J. C. L. M., Borgstein, P. J., Van Leeuwen, P. A. M., Gietema, H. A., Molenkamp, B. G., Muller, M. G. S., ... Meijer, S. (2005). Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma. Annals of Surgical Oncology, 12(6), 440-448. https://doi.org/10.1245/ASO.2005.06.013

Sentinel lymph node tumor load : An independent predictor of additional lymph node involvement and survival in melanoma. / Vuylsteke, Ronald J C L M; Borgstein, Paul J.; Van Leeuwen, Paul A M; Gietema, Hester A.; Molenkamp, Barbara G.; Muller, Markwin G Statius; Van Diest, Paul J.; Van Der Sijp, Joost R M; Meijer, Sybren.

In: Annals of Surgical Oncology, Vol. 12, No. 6, 06.2005, p. 440-448.

Research output: Contribution to journalArticle

Vuylsteke, RJCLM, Borgstein, PJ, Van Leeuwen, PAM, Gietema, HA, Molenkamp, BG, Muller, MGS, Van Diest, PJ, Van Der Sijp, JRM & Meijer, S 2005, 'Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma', Annals of Surgical Oncology, vol. 12, no. 6, pp. 440-448. https://doi.org/10.1245/ASO.2005.06.013
Vuylsteke, Ronald J C L M ; Borgstein, Paul J. ; Van Leeuwen, Paul A M ; Gietema, Hester A. ; Molenkamp, Barbara G. ; Muller, Markwin G Statius ; Van Diest, Paul J. ; Van Der Sijp, Joost R M ; Meijer, Sybren. / Sentinel lymph node tumor load : An independent predictor of additional lymph node involvement and survival in melanoma. In: Annals of Surgical Oncology. 2005 ; Vol. 12, No. 6. pp. 440-448.
@article{cdc345852cb749d08068757cf97529d1,
title = "Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma",
abstract = "Even though 60{\%} to 80{\%} of melanoma patients with a positive sentinel lymph node (SLN) have no positive additional lymph nodes (ALNs), all these patients are subjected to an ALN dissection (ALND) with its associated morbidity. The aim of this study was to predict the absence of ALN metastases in patients with a positive SLN by using features of the primary melanoma and SLN tumor load. Of 71 SLN-positive patients, 52 had metastasis limited to the SLN (group 1), and 19 had 1 positive ALN after ALND (group 2). The tumor load of the SLN was assessed by measuring the total surface area by computerized morphometry. Breslow thickness, ulceration and lymphatic invasion of the primary tumor, and total SLN metastatic area were tested as covariates predicting the absence of positive ALNs. The mean SLN metastatic area was 1.18 mm2 (group 1) and 3.39 mm2 (group 2) (P = .003) and was the only significant and independent factor after multivariate analysis (P = .02). None of the patients with both a Breslow thickness 2 had a positive ALN. SLN metastatic area can be used to predict the absence of positive ALNs in melanoma patients. In this study, patients with a Breslow thickness 2 seemed to have no positive ALN and had excellent survival. We hypothesize that this subgroup might not benefit from ALND. Prospective larger trials, using this model and randomizing between ALND and no ALND, should confirm this hypothesis.",
keywords = "Additional lymph node, Melanoma, Metastatic area, Sentinel lymph node",
author = "Vuylsteke, {Ronald J C L M} and Borgstein, {Paul J.} and {Van Leeuwen}, {Paul A M} and Gietema, {Hester A.} and Molenkamp, {Barbara G.} and Muller, {Markwin G Statius} and {Van Diest}, {Paul J.} and {Van Der Sijp}, {Joost R M} and Sybren Meijer",
year = "2005",
month = "6",
doi = "10.1245/ASO.2005.06.013",
language = "English (US)",
volume = "12",
pages = "440--448",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Sentinel lymph node tumor load

T2 - An independent predictor of additional lymph node involvement and survival in melanoma

AU - Vuylsteke, Ronald J C L M

AU - Borgstein, Paul J.

AU - Van Leeuwen, Paul A M

AU - Gietema, Hester A.

AU - Molenkamp, Barbara G.

AU - Muller, Markwin G Statius

AU - Van Diest, Paul J.

AU - Van Der Sijp, Joost R M

AU - Meijer, Sybren

PY - 2005/6

Y1 - 2005/6

N2 - Even though 60% to 80% of melanoma patients with a positive sentinel lymph node (SLN) have no positive additional lymph nodes (ALNs), all these patients are subjected to an ALN dissection (ALND) with its associated morbidity. The aim of this study was to predict the absence of ALN metastases in patients with a positive SLN by using features of the primary melanoma and SLN tumor load. Of 71 SLN-positive patients, 52 had metastasis limited to the SLN (group 1), and 19 had 1 positive ALN after ALND (group 2). The tumor load of the SLN was assessed by measuring the total surface area by computerized morphometry. Breslow thickness, ulceration and lymphatic invasion of the primary tumor, and total SLN metastatic area were tested as covariates predicting the absence of positive ALNs. The mean SLN metastatic area was 1.18 mm2 (group 1) and 3.39 mm2 (group 2) (P = .003) and was the only significant and independent factor after multivariate analysis (P = .02). None of the patients with both a Breslow thickness 2 had a positive ALN. SLN metastatic area can be used to predict the absence of positive ALNs in melanoma patients. In this study, patients with a Breslow thickness 2 seemed to have no positive ALN and had excellent survival. We hypothesize that this subgroup might not benefit from ALND. Prospective larger trials, using this model and randomizing between ALND and no ALND, should confirm this hypothesis.

AB - Even though 60% to 80% of melanoma patients with a positive sentinel lymph node (SLN) have no positive additional lymph nodes (ALNs), all these patients are subjected to an ALN dissection (ALND) with its associated morbidity. The aim of this study was to predict the absence of ALN metastases in patients with a positive SLN by using features of the primary melanoma and SLN tumor load. Of 71 SLN-positive patients, 52 had metastasis limited to the SLN (group 1), and 19 had 1 positive ALN after ALND (group 2). The tumor load of the SLN was assessed by measuring the total surface area by computerized morphometry. Breslow thickness, ulceration and lymphatic invasion of the primary tumor, and total SLN metastatic area were tested as covariates predicting the absence of positive ALNs. The mean SLN metastatic area was 1.18 mm2 (group 1) and 3.39 mm2 (group 2) (P = .003) and was the only significant and independent factor after multivariate analysis (P = .02). None of the patients with both a Breslow thickness 2 had a positive ALN. SLN metastatic area can be used to predict the absence of positive ALNs in melanoma patients. In this study, patients with a Breslow thickness 2 seemed to have no positive ALN and had excellent survival. We hypothesize that this subgroup might not benefit from ALND. Prospective larger trials, using this model and randomizing between ALND and no ALND, should confirm this hypothesis.

KW - Additional lymph node

KW - Melanoma

KW - Metastatic area

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=21244478180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244478180&partnerID=8YFLogxK

U2 - 10.1245/ASO.2005.06.013

DO - 10.1245/ASO.2005.06.013

M3 - Article

C2 - 15864481

AN - SCOPUS:21244478180

VL - 12

SP - 440

EP - 448

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -